Drug Trial Radar · NCT06681181
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Nov 18, 2024
Primary completion
Apr 23, 2026
Study completion Mar 11, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans. The study will test single doses of GSK4528287 to check for side effects, measure blood levels, and understand how it works in the body. The study will start with a small dose, and the dose will be increased for each new group of participants."
Conditions
- Colitis, Ulcerative
Interventions
GSK4528287Drug
GSK4528287 will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)Time frame: Up to Day 351 (End of follow up period)
- Number of Participants with Serious Adverse Events (SAE)Time frame: Up to Day 351 (End of follow up period)
- Number of Participants with Clinically Significant Changes in Laboratory ValuesTime frame: Up to Day 351 (End of follow up period)
- Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to Day 351 (End of follow up period)
- Number of Participants with Clinically Significant Changes in TelemetryTime frame: On Day 1
- Number of Participants with Clinically Significant Changes in 12 lead Electrocardiogram (ECG)Time frame: Up to Day 351 (End of follow up period)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.